Back to search results

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Abroad (travel likely)RecruitingPHASE2

Conditions

Diffuse Cutaneous Systemic Sclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Arizona Arthritis and Rheumatology Research PLLC, Mesa, Arizona, United States

    Contact: Study coordinator (Debra Mc Dermed) · Debra.McDermed@azarthritis.com · +1 602 386 4970
    Contact: Principal Investigator (Nehad Soloman)

  • UCLA, Los Angeles, California, United States

    Contact: Study coordinator (Lauren Nam) · lnam@mednet.ucla.edu · +1 310 488 0162
    Contact: Principal Investigator (Suzanne Kafaja)

  • Hoag Hospital, Newport Beach, California, United States

    Contact: Study coordinator (Vicki Tan) · vicki.tan@hoag.org · +1 949 791 3049
    Contact: Principal Investigator (Christine Thai)

  • Clinical Res Of W Florida, Clearwater, Florida, United States

    Contact: Study coordinator (Amber Tipker) · atipker@crwf.com · +1 727 466 0078
    Contact: Principal Investigator (Rodney Daniel)

  • GNP Research, Cooper City, Florida, United States

    Contact: Study coordinator (Melissa Pierce) · melissa@gnpresearch.com · +1 754 248 3589
    Contact: Principal Investigator (Mark Jaffe)

  • IRIS Research and Development, Plantation, Florida, United States

    Contact: Study coordinator (Jhon Galindo) · jgalindo@irisrheumatology.com · +1 954 476 2338
    Contact: Principal Investigator (Guillermo Valenzuela)

  • Sarasota Arthritis Res Ctr, Sarasota, Florida, United States

    Contact: Study coordinator (Carole Kringel) · carole@arthritiscenters.net · +1 941 365 0770
    Contact: Principal Investigator (Jaishree Manohar)

  • University of Chicago Hospitals, Chicago, Illinois, United States

    Contact: Study coordinator (J Heannhehbelle Rosier) · jrosier@uchicagomedicine.org · +1 773 702 3853
    Contact: Principal Investigator (Michael Macklin)

  • UMC New Orleans, New Orleans, Louisiana, United States

    Contact: Study coordinator (Sean Barry) · sbarr2@lsuhsc.edu
    Contact: Principal Investigator (Stephen Lindsey)

  • Uni Of Michigan Health System, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Christopher Floyd) · cjfloyd@med.umich.edu · +1 734 936 5504
    Contact: Principal Investigator (Carleigh Zahn)

  • Wayne State University, Detroit, Michigan, United States

    Contact: Study coordinator (Biljana Basic-Panic) · bbasicpanic@med.wayne.edu
    Contact: Principal Investigator (Ilyes Benchaala)

  • Clinical Research Inst of MI, Saint Clair Shores, Michigan, United States

    Contact: Study coordinator (Amelia Paliewicz) · apaliewicz@researchmi.com · +1 586 777 7577
    Contact: Principal Investigator (Andrew Sulich)

  • Hospital for Special Surgery, New York, New York, United States

    Contact: Study coordinator (Liza Morales) · moralesli@HSS.EDU · +1 212 774 2596
    Contact: Principal Investigator (Kimberly Showalter Lakin)

  • West Tennessee Research Institute, Jackson, Tennessee, United States

    Contact: Study coordinator (Sherry Wiggins) · swiggins@arthritisclinic.org · 17316330119
    Contact: Principal Investigator (Jacob A Aelion)

  • Arthritis and Rheumatology Ins, Allen, Texas, United States

    Contact: Study coordinator (Samina Shehzad) · shehzad.s@dfwarthritis.com
    Contact: Principal Investigator (Megha Patel Banker)

  • Novel Research LLC, Bellaire, Texas, United States

    Contact: Study coordinator (Hassan Khan) · khan@novelresearch.net
    Contact: Principal Investigator (Wajeeha Yousaf)

  • Prolato Clinical Research Center, Houston, Texas, United States

    Contact: Study coordinator (Mohammad Alsayed) · malsayed@prolato.org · +1 832 338 9118
    Contact: Principal Investigator (Michelle Eisenberg)

  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, San Miguel de Tucumán, Argentina

  • Novartis Investigative Site, Graz, Austria

  • Novartis Investigative Site, Leuven, Belgium

  • Novartis Investigative Site, Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site, Curitiba, Paraná, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Sao Jose Rio Preto, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Nanning, Guangxi, China

  • Novartis Investigative Site, Zhengzhou, Henan, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Chengdu, Sichuan, China

  • Novartis Investigative Site, Ningbo, Zhejiang, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Tianjin, China

  • Novartis Investigative Site, Medellín, Antioquia, Colombia

  • Novartis Investigative Site, Bogota, Cundinamarca, Colombia

  • Novartis Investigative Site, Bogota, Cundinamarca, Colombia

  • Novartis Investigative Site, Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site, Bogotá, Colombia

  • Novartis Investigative Site, Medellín, Colombia

  • Novartis Investigative Site, Dijon, France

  • Novartis Investigative Site, Le Mans, France

  • Novartis Investigative Site, Lille, France

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Rennes, France

  • Novartis Investigative Site, Strasbourg, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Würzburg, Bavaria, Germany

  • Novartis Investigative Site, Jena, Thuringia, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Alexandroupoli, Greece

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Pécs, Baranya, Hungary

  • Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Kochi, Kerala, India

  • Novartis Investigative Site, Mumbai, Maharashtra, India

  • Novartis Investigative Site, Mumbai, Maharashtra, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, New Delhi, New Delhi, India

  • Novartis Investigative Site, Jaipur, Rajasthan, India

  • Novartis Investigative Site, Ancona, AN, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Rozzano, MI, Italy

  • Novartis Investigative Site, Modena, MO, Italy

  • Novartis Investigative Site, Palermo, PA, Italy

  • Novartis Investigative Site, Pavia, PV, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Verona, VR, Italy

  • Novartis Investigative Site, Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site, Toyoake, Aichi-ken, Japan

  • Novartis Investigative Site, Kitakyushu, Fukuoka, Japan

  • Novartis Investigative Site, Maebashi, Gunma, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Yokohama, Kanagawa, Japan

  • Novartis Investigative Site, Suita, Osaka, Japan

  • Novartis Investigative Site, Iruma-gun, Saitama, Japan

  • Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan

  • Novartis Investigative Site, Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site, Shinjuku Ku, Tokyo, Japan

  • Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan

  • Novartis Investigative Site, Toyama, Toyama, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Hiroshima, Japan

  • Novartis Investigative Site, Ishikawa, Japan

  • Novartis Investigative Site, Kyoto, Japan

  • Novartis Investigative Site, Cheras, Kuala Lumpur, Malaysia

  • Novartis Investigative Site, Kuala Lumpur, Malaysia

  • Novartis Investigative Site, Chihuahua City, Chihuahua, Mexico

  • Novartis Investigative Site, Guadalajara, Jalisco, Mexico

  • Novartis Investigative Site, Mexico City, Mexico City, Mexico

  • Novartis Investigative Site, Mexico City, Mexico City, Mexico

  • Novartis Investigative Site, Monterrey, Nuevo León, Mexico

  • Novartis Investigative Site, Bydgoszcz, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Coimbra, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Vila Nova de Gaia, Portugal

  • Novartis Investigative Site, Seoul, Seoul, South Korea

  • Novartis Investigative Site, Busan, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Málaga, Andalusia, Spain

  • Novartis Investigative Site, Valencia, Valencia, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, Changhua, Taiwan

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, Taichung, Taiwan

  • Novartis Investigative Site, Taoyuan, Taiwan

  • Novartis Investigative Site, Khon Kaen, THA, Thailand

  • Novartis Investigative Site, Bangkok, Thailand

  • Novartis Investigative Site, Istanbul, Fatih, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Sihhiye-Altindag, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)

  • Novartis Investigative Site, Basingstoke, Hampshire, United Kingdom

  • Novartis Investigative Site, Bristol, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Ho Chi Minh City, VNM, Vietnam

  • Novartis Investigative Site, Ho Chi Minh City, Vietnam

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)